DUBLIN, October 18, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Nerve Repair And Regeneration Market Analysis By Product, By Surgery And Segment Forecasts to 2024" report to their offering.
The global nerve repair and regeneration market is forecast to reach a value of USD 15.7 billion by 2024, according to this new report.
In January 2016, The EU Horizon 2020 program funded a research project AUTOSTEM' launched by the NUI Galway's Regenerative Medicine Institute (REMEDI) amounting toUSD 6.73 million. This project is to develop a robotic stem cell production factory, involved in fully automated manufacturing of stem cells in large volumes; thus, having an edge over the old traditional techniques. Also, this technique will treat a range of therapies pertaining tocancer,arthritis, diabetes and other complications.
North America dominated the market in 2015 owing to the technological advancements in the region and the introduction of new devices by the manufacturers. In 2015, U.S proved to be the most potential market. The rise in number of cases withinjuries in the Central Nervous System (CNS), including injuries to the spinal cord and the brain,and increase in the governmentinitiatives and funding,as well as funding fromvarious other agencies were some of the major reasons responsible for the growth.
In March 2016, Baxter International, Inc. completed the CE marking, the indication for marketing of HEMOPATCH', the ready-to-use surgical patch in the European market. This patch was approved for use in dural defect repair, for treatingtraumatic injuries of the brain, CNS, andas a surgical sealant to contain leakage of bodily fluids in otherbody parts, oras a hemostatic device to prevent the loss of blood.
APAC is expected to be the fastest growing region of the nerve repair and regeneration market. Aging population, technological advancements, and unmet medical needs in this region are some of the reasons for the growth of the market
In February 2016, Indian scientists working for Revita Life Sciences and Bioquark, Inc. gained permission to conduct clinical trials in 20 clinically dead patients to bring specific parts of their central nervous system back to life. Combination of therapies are to be applied including injecting the brain with stem cells, cocktail of peptides, use of lasers and nerve stimulation techniquesthat have been proven successful in reviving comatose patients.A blend of regenerative medicine tools and treatment devices are to be employed to achieve success with such a complex undertaking.
Manufacturers are collaboratingwith the aim of combining the use of innovative devices and therapies to improve treatment efficiency and provide better therapy outcomes
In November 2012, UCB (Euronext Brussels) and NewBridge Pharmaceuticals entered into an agreement to engage in geographical expansion of its core products (Neupro, Vimpat, and Cimzia)to include majority of the African and Middle east countries in its distribution channels. On the other hand, Newbridge Pharmaceuticals is to focus on product commercialization, gaining regulatory approvals from local bodies, and perform pharmacovigilance. This agreement is estimated to elevate the uptake of products related to CNS and immunologic diseases in the Middle-east and Africa region.
- AxoGen, Inc.
- Baxter International, Inc.
- Boston Scientific, Inc.
- St. Jude Medical, Inc.
- Cyberonics, Inc.
- Integra Lifesciences Corporation
- Medtronic plc.
- Stryker Corporation
- Polyganics B.V.
1. Methodology and Scope
2. Executive Summary
3. Nerve Repair and RegenerationIndustry Outlook
4. Nerve Repair and Regeneration Product Outlook
5. Nerve Repair and RegenerationSurgery Outlook
6. Nerve Repair and Regeneration RegionalOutlook
For more information about this report visit http://www.researchandmarkets.com/research/jt3mff/nerve_repair_and
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets